Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
100.8 EUR | +1.31% | +1.66% | +0.60% |
03:02pm | BIOMÉRIEUX : Berenberg raises its target | CF |
Apr. 23 | Deutsche Bank Initiates BioMérieux Coverage at Purchase | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With a 2024 P/E ratio at 25.6 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.60% | 12.59B | B+ | ||
-12.53% | 7.42B | B- | ||
+2.62% | 5.35B | B | ||
-1.37% | 4.51B | C | ||
+5.16% | 4.47B | C | ||
-51.93% | 3.21B | D+ | ||
+11.34% | 2.71B | - | - | |
-18.23% | 1.96B | B- | ||
-11.07% | 1.73B | D+ | ||
-6.06% | 1.63B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux